”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

A new wound dressing that kills all types of bacteria without harming the body Even resistant bacteria

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

The Amferia story:

Amferia was born in Gothenburg, Sweden, when three PhD researchers who had been collaborating for five years had the idea to combine their findings. In 2016, after several conversations among themselves, Amferia founders Saba Atefyekta, Anand Kumar Rajasehkaran and Martin Andersson conceived a new class of antimicrobial material while working at Chalmers University of Technology .

The approach was to utilise antimicrobial peptides—a potent antimicrobial molecule that Saba Atefyekta was investigating for biomaterial applications — in combination with a new amphiphilic hydrogel developed by Anand Rajasekharan for his PhD research on synthetic bone.

Within the first two weeks, we noted that the idea was sound and worked perfectly, which is a rarity in science” 

During a conference visit to Montreal in May 2016, Saba, Anand and Martin dove deeper into discussions and realized their combined research had uncovered potential for real-world biomedical applications. ”After all these years of research we suddenly realised how to combine our findings. It was a eureka moment,” said Saba.

Excited by their discoveries, Saba and Anand returned to the lab and initiated the first trial runs, synthesizing the material and testing it on bacteria. “Within the first two weeks, we noted that the idea was sound and worked perfectly, which is a rarity in science,” said Anand.

From basic research to a high-impact product

The company:

After months of trials and more trials focused on optimizing the commercial viability of the product, the founders knew their idea had life beyond the lab and science publications. They knew they could develop a new, innovative product to target and kill bacteria in medical applications.  

The team immediately reached out to the innovation arm of Chalmers University and filed for a patent. Then they engaged in intense market research, while continuing further experiments on resistant bacteria.

By late 2017, the first patent was filed, the hydrogel had been proven to kill bacteria — including numerous resistant bacteria — and was safely used in biological environments without toxicity. Most importantly, the founders agreed their first product using the new technology should address wound care.

By late 2017, the first patent was filed, the material proven to kill bacteria including numerous resistant bacteria

Since then, the company has worked hard and successfully scaled the technology, completed clinical evaluations in both human and animal wound care and are now preparing for their regulatory approvals.  

With further support from Chalmers innovation Office and a seed funding from Chalmers Ventures, Amferia was officially incorporated in September 2018. Both Anand and Saba, completed their PhDs and jumped on board to continue their full-time journey, translating fundamental research into new products for human and animal health.

Today Amferia is a talented team of seven, with dedicated personnel for business development, sales, clinical development, product development and production. 

Protected by strong patents granted in Europe, the U.S. and China

Patent portofolio:

Amferia’s innovation is protected by three strong patent families. The basic patent is already in force in China, the U.S. and Europe, and pending in several other countries. Ongoing R&D continues to generate new patent applications.

Currently, strong patent protection extends over Amferia’s core technology and key intellectual property, creating the potential for rapid and robust growth into human and animal health care. Because the patents extend to both the U.S. and Europe, Amferia is poised to enter partnerships that enable market leadership well into the future.  

Amferia's patent families

  • — Antimicrobial hydrogel technology (Application nr. 17512773) was filed in 6 countries and granted in Europe, the US and China, pending in the remaining countries. The patent is the foundation of Amferia's innovation and claims a new amphiphilic antimicrobial material, a device comprising the antimicrobial material and a method to produce the same.
  • — Mesoporous elastomer technology is Amferia's second patent family that claims a tough and nanostructured elastomeric material for various medical device applications.
  • — Utilizing antimicrobial technology in spray form was filed in 2020 and is currently granted in Sweden (1951495-9) and expected to be granted in other countries by early 2023. Utilizing the Amferia antimicrobial technology in spray form that can be applied to deeper wounds, bleeding wounds and surfaces for rapid disinfection.

Named by the science journal Nature and others

Recognition:

Amferia has been recognised by numerous organisations for its innovative research, entrepreneurial drive, business traction in multiple sectors and swift progress towards clinical translation. 

During 2019, Venture Cup Sweden named Amferia as the ‘Startup-of-the year  while the scientific journal Nature named Amferia as ‘one-to-watch  — on a list of the top 44 pioneering university spin-offs with excellent scientific groundwork

Amferia’s Co-founder and Sales Director, Dr. Saba Atefyekta, was recognised as a pioneering female entrepreneur by Women-in Tech Sweden and the Prince Daniel Fellowship.

Meet the team

Team and board:

Anand Rajasekharan, PhD, CEO & Co-founder. Anand holds a PhD in Materials Science from Chalmers University of Technology and is one of the inventors of the material platform serving Amferia’s healthcare technology.

Saba Atefyekta, PhD, Sales Director & Co-founder. Co- inventor behind Amferia’s technology.  Holds a PhD in Materials Science from Chalmers University and her thesis describes the antimicrobial platform of Amferia’s technology. Today, she leads business development in human and animal health.

Martin Andersson, PhD, R&D Director & Co-founder. Fifteen years’ experience in biomedical research with 100 scientific publications. He has previously started a med-tech company for bone implants with successful implementation of products into the market. Professor, Materials Science at Chalmers University.

Ingvar Karlsson, CFO. Previously CFO from both public and private companies covering life science and medtech, automotive and premium consumer goods spanning over 40 years.

Daniel Hagberg, PhD, CTO. Ten years experience in product development and manufacturing from the speciality chemicals and healthcare industry. PhD in Materials Science from Royal Institute of Technology, Sweden

Parvin Zamani, Director of Partnerships & Strategy. 25 years experience in life-science business development. Has had various leadership roles within sales, strategy and business development from both public and private life-science and biotech companies covering pharma, medtech and diagnostics.

Rojan Modaresi, DVM, PhD, Product Manager, Animal Health.  Responsible for Amferia’s wound products for animal care and works at the interface between product development and customer interaction at veterinary clinics across Europe. Doctor of Veterinary Medicine and PhD in Microbiology from Urmia University, Iran.

Edvin Blomstrand, PhD., Research Engineer. Responsible for the product design and device optimization for wound care applications. Skilled in material design, antimicrobial testing and cell-material assessment. PhD in Materials Science from Chalmers University.

Board of Directors

Agneta Edberg, Chair. Previously Nordic Senior VP of Mylan, COO Bactiguard, Marketing Director at Pharmacia, Pfizer and CEO NM Pharma and several life science board assignments

Björn Engström. Previously Co-founder and Copywriter at Forsman & Bodenfors, several board assignments in scale-up companies and experienced in life-science marketing

Saba Atefyekta, PhD, Co-founder. PhD in Materials Science from Chalmers University and co-inventor of Amferia Technology

Martin Andersson, PhD, Co-founder. Professor in Materials Science at Chalmers University and co-inventor of Amferia Technology. Co-founder of Promimic AB, an bone-implant scale-up.

Ulrika Åberg. Investment manager at Almi Invest, previously IP lawyer at Mölnlycke Health care.

Alexandra De Wever Treschow, PhD, Experienced CEO of life science companies, presently CEO of NordX Pharma, previously at Aprovix AB, PhD in Gene Therapy

Jonas Bergman, Investment manager at Chalmers Ventures, previously CEO of life science company Integrum, and consultant at Triathlon AB 

Advisors

Dr. Christian Nees, Clinical Advisor Animal Health, Veterinary surgeon with 35 years of experience in surgery and wound care. Previously the head of Animal Health Hospital in Weingarten (Kleintierzentrum Weingarten), Germany.

Strong support for Amferia

Partners and funding:

Amferia’s first human clinical study published

June 26, 2023

We are thrilled to share that our dedicated team at Amferia in collaboration with Chalmers tekniska högskola has published a randomised controlled study in the Journal of Wound Care that demonstrates the outstanding antibacterial performance of our hydrogel wound dressing.  We studied our wound dressing on intact human skin as a model to evaluate the speed and efficacy of the dressing to kill bacteria — and the results were truly remarkable!

By utilizing the Amferia Antimicrobial Hydrogel technology, we eradicated bacteria when placed in contact with skin within a short period of three hours.

By utilizing the Amferia Antimicrobial Hydrogel,   bacteria was eradicated within three hours.

These findings demonstrate the potential of our antibacterial wound dressing to significantly reduce the risk of infection in wounds, offering new possibilities for improved patient outcomes. This study lays the foundation for our future clinical studies in human wounds.

You can now access the article via the link:  https://lnkd.in/eTV7nMZg

Amferia raises SEK 15.4 million to launch innovative antimicrobial wound care dressing

January 27, 2023

The financing was raised from Almi Invest, Chalmers Ventures, and with several angel investors to support launch of Amferia’s first product, a wound care dressing with a patented hydrogel that actively combats infections and kills antibiotic-resistant bacteria.

Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds from simple skin injuries, post-operative wounds to chronic wounds and trauma / burn wounds. The WHO predicts that antibiotic-resistant infections, including those from wounds could become one of the leading causes of both illness and death over the next ten years.

“I am grateful to all our committed investors: Every year, nearly 1 million people die globally because of infections caused by antibiotic-resistant bacteria and at least a quarter of those infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives. The resistance problem is even more challenging within the animal health sector.”, says Agneta Edberg, Chairperson of Amferia.

Amferia's wound care solution is a game-changer and will save lives.

Amferia's patented material, an antimicrobial amphiphilic hydrogel, has been developed through several years of research in collaboration with Chalmers University of Technology and contains molecules inspired by body’s own immune system. The material instantly kills all bacteria (even antibiotic resistant) by binding to and disrupting their cell membranes, all without damaging the body’s own cells or entering the bloodstream. The first product from this technology is a hydrogel wound-care dressing for dry-to-low exuding wounds, while the material is also being investigated for development in several other areas, including sprays for deep wounds, and coatings for implants and a variety of catheters. In September of 2022, Amferia launched its first wound dressings for animal health in Sweden and plan on expanding across Europe during 2023. In parallel, the company is preparing to file for regulatory clearance in the US for human health.

The wound care market currently generates sales for over US $ 2 billion globally with a projected CAGR of 5 %. However, existing alternatives on the market often contain antibiotics that carry the risk of causing resistance or antiseptics that may harm body cells and negative environmental impact.

We already have our first product on the market for animal wound care in Sweden

“The investment enables us to perform three key tasks: scale up and launch our products for animal health in Europe, file for FDA clearance of the application for human health and thirdly initiate more clinical studies in both market segments. This ambition is supported by the fact that we already have our first product on the market for animal wound care in Sweden”, says Anand Kumar Rajasekharan, CEO of Amferia.

Pre-clinical research on new antimicrobial spray and coating technology published

January 26, 2023

Amferia announced today that it has, in collaboration with Chalmers University of Technology, published two important scientific articles in peer-reviewed journals that describe the pre-clinical studies of its platform technology, Amphiphilic Antimicrobial Hydrogel as sprays and coatings for various medical device applications.

Amferia’s platform technology is an amphiphilic antimicrobial hydrogel material that can rapidly bind and kill all types of bacteria, even resistant bacteria, without harming the body. In an effort to enable further applications of this material, Amferia collaborated with Chalmers University of Technology to test and develop the patented technology as sprayable formulation and as coatings fight off bacterial infections in medical devices.

Today, the extensive pre-clinical data from this research has been published in two scientific articles in peer-reviewed journals*. The research was built on the formulation of the Amphiphlic Antimicrobial Hydrogel as small discrete particles, which were then further developed as sprayable form for wound care and as a coating on existing materials like silicone catheters. The results from these studies show powerful antimicrobial effect, safety to human cells while being stable in biological environments such as serum.

The material has been shown to be effective against many different types of bacteria, including those that are resistant to antibiotics

Martin Andersson, Professor at Chalmers University and Co-founder of Amferia − “Our innovation can have a dual impact in the fight against antibiotic resistance. The material has been shown to be effective against many different types of bacteria, including those that are resistant to antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA), while also having the potential to prevent infections and thus reduce the need for antibiotics,.”

The research was undertaken based on the strong potential of Amferia’s technology, but also based on a clear need from the human and animal health care system on fighting infections in the context of deep infected wounds as well as for various medical devices such as urinary catheters. Amferia and Chalmers will continue to collaborate on this research and are planning to further study the use of the new formulations in clinical settings, both for human and animal care.

We are seeing the great potential of our technology going beyond wound care into the realm of broader medical devices

Anand Rajasekharan,CEO of Amferia − “This is an important achievement for Amferia as we are seeing the great potential of our technology going beyond wound care into the realm of broader medical devices such as coatings and sprayable systems. Our current product is a wound dressing and we look forward to follow-up the same with these pipeline products that will have a stronger impact for addressing antibiotic resistance.”

*The scientific article on the formation of antimicrobial hydrogel particles as sprays and its in-vitro efficacy, safety and stability is published in Cross-linked lyotropic liquid crystal particles functionalized with antimicrobial peptides, Blomstrand et. al. 2022

*The scientific article on the utilisation of these particles as coatings on silicone materials is published in MultifunctionalSurface Modification of PDMS for Antibacterial Contact Killing andDrug-Delivery of Polar, Nonpolar, and Amphiphilic Drugs, Stepulane et. al. 2022

Agneta Edberg appointed chairperson

July 28, 2022

Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales &Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan NordicPharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaurd that manufactures a variety of antimicrobial device. Today, she works on theBoard of cutting-edge life-science SME’s guiding the companies for future success. Agneta’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia − “It is an honour to work with Agenta, whose impressive knowledge of the field and guidance greatly strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia.”

Agneta Edberg − “Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat”

Amferia at the European Wound Management Association (EWMA) congress 2022 in Paris

May 17, 2022

EWMA is an important congress that brings together clinicians and healthcare  industry for important discussions within wound care for humans and animals. Amferia is eager to present our science, antimicrobial technology and introduce our first wound dressings for animal and human wound  care. We welcome all attendees to our stand located in

room 252A at the  congress venue, Palais  des Congrès de Paris, to know more about Amferia and  clinical evidence for human and animal wound care as well as for an  introduction to our soon-to-be launched wound dressings for animal wound  care. We also invite all  attendees to our scientific talk at the symposium for Veterinary Wound  Healing Association (VWHA) on 24th May at 08:45 hrs room 252A.

US patent granted

May 9, 2022

Amferia AB announced today that it has been granted the foundational patent by the United States Patent and Trademark Office (USPTO)for its innovative antimicrobial material based on an amphiphilic antimicrobial hydrogel. The company is now in its final stages of product development for wound care applications and aims to launch the first product within animal health during 2022.

Top 100 research based innovations of 2021

May 26, 2021

Amferia’s technology recognized as one of the top 100 research based innovations of 2021 by the Royal Swedish Academy of Engineering Sciences.

Amferia & Triolab announce partnership to launch innovative wound care products for animal health

May 6, 2021

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab’s partnership will build on extensive data and feedback from Amferia’s ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.

Amferia raises SEK 6.2 million in pre-seed investment

January 22, 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let’s Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warme, Investment Manager at Almi Invest.

Amferia establishes R&D operations at AstraZeneca’s BioVentureHub

October 28, 2019

Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.

Thank you! Your message has been received. Talk to you soon!
Oh no! Something went wrong while submitting the form. Please try again.